Pre-quarterly Results Communication
Foreign Exchange Average exchange rates for Q1 2014 were . Foreign exchange is not expected to have a material effect on revenues in Shire's Q1 2014 results.
The Washington Post
Novartis to Shire Said to Consider Bidding for ThromboGenics
Novartis AG and Shire Plc are among drugmakers weighing offers for Belgian eye-medicine company ThromboGenics NV, people familiar with the matter said.
Shire PLC Receives "Overweight" Rating from Barclays
's stock had its "overweight" rating restated by Barclays in a research note issued on Monday, AnalystRatingsNetwork reports.
Deadly Bowel Infection Draws Drugmakers Seeking Cures
Drugmakers led by Merck & Co. and Sanofi are searching for new weapons against a deadly bacteria implicated in hospital and nursing-home infections.
Shire PLC Rating Reiterated by Goldman Sachs
's stock had its "strong-buy" rating reiterated by equities researchers at Goldman Sachs in a research report issued on Tuesday, AnalystRatings.Net reports.
Shire Plc: Pharmaceuticals and Healthcare - Company Profile, SWOT and ...
The profile contains a company overview, key facts, major products and services, SWOT analysis, business description, company history, financial analysis, mergers and acquisitions, recent developments, key employees, company locations and subsidiaries, employee biographies as well as competitive benchmarking data.
Shire PLC Given Outperform Rating at BNP Paribas
's stock had its "outperform" rating restated by research analysts at BNP Paribas in a report released on Friday, Stock Ratings News reports.
Shire Submits INTUNIV (Guanfacine Extended Release) Marketing...
March 27, 2014 - Shire plc today announced the acceptance of submission of a Marketing Authorisation Application by the European Medicines Agency for their once-daily, non-stimulant guanfacine extended release for the treatment of Attention Deficit/Hyperactivity Disorder in children/adolescents aged 6-17 years.
The Motley Fool
Will Shire PLC Build Or Buy Its Future?
The ideal in the biotech and pharma world may be for a company to develop a strong internal R&D engine that regularly churns out potential blockbuster compounds, but the reality is that most companies have to turn to partnerships and acquisitions to manage risk and maintain growth.
Shire PLC PT Raised to $173.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co.' s target price would indicate a potential upside of 17.22% from the stock's previous close.